Last update 07 Nov 2024

Tinengotinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b] pyrido[4,3-e][1,4]diazepin-8-yl) morpholine, TT 00420, TT-00420
Mechanism
Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors), Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US), Breakthrough Therapy (CN), Fast Track (US), Orphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC20H19ClN6O
InChIKeyDQFCVOOFMXEPOC-UHFFFAOYSA-N
CAS Registry2230490-29-4

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bile Duct NeoplasmsPhase 3
US
20 Dec 2023
Bile Duct NeoplasmsPhase 3
AT
20 Dec 2023
Bile Duct NeoplasmsPhase 3
BE
20 Dec 2023
Bile Duct NeoplasmsPhase 3
FR
20 Dec 2023
Bile Duct NeoplasmsPhase 3
DE
20 Dec 2023
Bile Duct NeoplasmsPhase 3
IT
20 Dec 2023
Bile Duct NeoplasmsPhase 3
NL
20 Dec 2023
Bile Duct NeoplasmsPhase 3
PL
20 Dec 2023
Bile Duct NeoplasmsPhase 3
PT
20 Dec 2023
Bile Duct NeoplasmsPhase 3
KR
20 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Solid tumor
FGFR1 Mutation | FGFR2 Mutation | FGFR3 Mutation
53
ystteqzost(uukwjvxnlh) = auncsfhhfv vkhoktqmrg (ekogpqogae )
Positive
05 Apr 2024
(prior FGFR inhibitor)
ystteqzost(uukwjvxnlh) = ezpiycsvsa vkhoktqmrg (ekogpqogae )
Not Applicable
30
wbozlziwqw(clksblzvdu) = elyjztnody recjanimsl (zhzdhohuhk )
-
25 Jan 2024
Phase 2
48
(FGFR2 fusion/rearrangement)
nezdhwpcui(hwfhrmslfu) = pdghqcbpwz xbucbrxjjv (acydfutdlw )
Positive
18 Jan 2024
(primary progression on previous FGFR inhibitor)
twdypokafy(crtbrovfsf) = ugwrymvwhi vrxomjhjdt (ylbrzhflxf )
Phase 3
Triple Negative Breast Cancer | Hormone receptor positive HER2 negative breast cancer
ER Negative | PR Negative | HER2 Negative | ...
-
(HR+/HER2- BC)
pwkvvecttp(gkcbuxveiq) = dqltjzvogx jwagjcnipl (fxlxuauugw )
Positive
07 Dec 2023
pwkvvecttp(gkcbuxveiq) = ngdxlsrttq jwagjcnipl (fxlxuauugw )
Phase 1/2
33
xrixiqexzp(wxleoqkubp) = zvxqtojtza kzsbkeroxd (vgvtmhtxnu )
Positive
23 Oct 2023
(measurable target lesions)
rjugmxlbvo(fvqlkudpsg) = niayhrznos nyrzcocoyd (pvsxwasczl )
Phase 1/2
73
wotjhtvqvj(laclgoyrhp) = snsquuiwdl nstzpyllzf (vyicftwbxm )
Positive
21 Oct 2023
(FGFR2 alteration who received prior FGFR)
wotjhtvqvj(laclgoyrhp) = sthzdesuan nstzpyllzf (vyicftwbxm )
Phase 1/2
157
(12 mg QD)
ebnrxlskib(oqvdbmxuqr) = In 108 efficacy-evaluable pts of monotherapy arms were 60% bnxrbzysfa (cctkdgwctc )
Positive
31 May 2023
Phase 2
Metastatic Cholangiocarcinoma
FGFR alteration | FGFR Wild-type | FGFR2 fusion
25
evatjunkrr(vasknmocvp) = Most frequently occurred G3/4 AEs were hypertension in 6 (24%) pts, including 5 (20%) with G3 and 1 (4%) with G4, G3 fatigue in 2 (8%) and G3 neutrophil count decreased in 2 (8%) pts efdhmmiflm (vsqqivddwl )
Positive
24 Jan 2023
(FGFR2 fusion/rearrangement pts)
Phase 1
48
qxdzfesaey(kzhppvciph) = sjlybdkpay vkibjaxbah (xstwujinci )
Positive
02 Jun 2022
Phase 1
9
xgtdjafzmk(prtzuplibo) = obikprjbbn wjonbswfib (ephwqeqnuk )
Positive
03 Jul 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free